Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab

Background/AimsSeveral recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current stu...

Full description

Saved in:
Bibliographic Details
Published in:Intestinal research 2014, 12(4), , pp.281-286
Main Authors: Kim, Nam Hee, Jung, Yoon Suk, Moon, Chang Mo, Lee, Shin Yeong, Kim, Eun Ran, Kim, Young Ho, Lee, Chang Kyun, Lee, Suck Ho, Kim, Jae Hak, Huh, Kyu Chan, Yoon, Soon Man, Song, Hyun Joo, Boo, Sun-Jin, Jang, Hyun Joo, Kim, You Sun, Lee, Kang-Moon, Shin, Jeong Eun, Park, Dong Il
Format: Article
Language:English
Subjects:
Crohn disease
Infliximab
Original
Prognosis
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/AimsSeveral recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.MethodsPatients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.ResultsOf the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P
ISSN:1598-9100
2288-1956
DOI:10.5217/ir.2014.12.4.281